Conventional and atypical antipsychotics in the elderly: A review

Clinical Drug Investigation

Volumn 23, Issue 5, 2003, Pages 287-322

  Gareri, Pietro ^a   De Fazio, Pasquale ^a   Stilo, Mariagrazia ^a   Ferreri, Guido ^a   De Sarro, Giovambattista ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOTIAPINE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR; FLUPHENAZINE; GLUTAMIC ACID; HALOPERIDOL; LIVER ENZYME; NEUROLEPTIC AGENT; NEUROTRANSMITTER; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PROMAZINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SEROTONIN; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TIAPRIDE; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

AGE; AGRANULOCYTOSIS; AKATHISIA; BLOOD DYSCRASIA; BRAIN EDEMA; CONFUSION; CONSTIPATION; DEPRESSION; DIABETIC KETOACIDOSIS; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DYSTONIA; EJACULATION DISORDER; GALACTORRHEA; GENETIC POLYMORPHISM; GYNECOMASTIA; HALLUCINATION; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HEMATOLOGIC DISEASE; HIP FRACTURE; HUMAN; HYPERPROLACTINEMIA; HYPERREFLEXIA; HYPERSALIVATION; HYPERTENSION; IMPOTENCE; INFERTILITY; INSOMNIA; LIVER INJURY; MELANOSIS; MUSCLE WEAKNESS; MYALGIA; MYDRIASIS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NEUROPATHOLOGY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARALYTIC ILEUS; PARKINSONISM; PAROTITIS; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RASH; RECEPTOR AFFINITY; RETINOPATHY; REVIEW; SCHIZOPHRENIA; SEIZURE; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN ALLERGY; SKIN DISCOLORATION; SOMNOLENCE; SYNCOPE; TARDIVE DYSKINESIA; TREMOR; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0038554430     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323050-00001     Document Type: Review

References (206)

1. Keverne EB. GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses. Brain Res Bull 1999; 48: 467-73
2. Gavrilova SI, Kalyn IB. Social and environmental factors and mental health in the elderly. Vestn Ross Akad Med Nauk 2002; 9: 15-20
3. Ostling S, Skoog I. Psychotic symptoms and paranoid ideation in a nondemented population-based sample of the very old. Arch Gen Psychiatr 2002; 59: 60-1
4. Leysen JE, Janssen PMF, Heylen L, et. al. Receptor interactions of new antipsychotics: relation to pharmacodynamic and clinical effects. Int J Psychiatr Clin Pract 1998; 2: S3-S17
5. Delay J, Deniker P, Harl JM. Traitements d'etats confusionnels par le chlorhydrate de diethylaminopropyl-N-chlorophenothiazine (4560 RP). Ann Med Psychol 1952; 110: 398-403
6. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20: 140-4
7. Toru M. Biological research on schizophrenia. Psychiatry Clin Neurosci 1998; 52 Suppl.: 170-2
8. van Rossum JM. The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966; 160: 492-4
9. Randrup A, Munkvad I. Influence of amphetamines on animal behavior: stereotypy, functional impairment and possible animal-human correlations. Psychiatr Neurol Neurochir 1972; 75: 193-202
10. Egan MF, Weinberger DR. Neurobiology of schizophrenia. Curr Opin Neurobiol 1997; 7: 701-7
11. Grandy DK, Zhang Y, Bouvier C, et al. Multiple human D5 dopamine receptor genes: a functional receptor and two pseudogenes. Proc Natl Acad Sci U S A 1991; 88: 9175-9
12. Jackson DM, Westlind-Danielson A. Dopamine receptors: molecular biology, biochemistry and behavioral aspects. Pharmacol Ther 1994; 64: 291-369
13. Gerfen CR, Engber TM, Mahan LC, et al. D1 and D2 dopamine receptor-regulated gene expression of nigrostriatal and striatopallidal neurons. Science 1990; 250: 1429-32
14. Gingrich JA, Caron MG. Recent advances in the molecular biology of dopamine receptors. Ann Rev Neurosci 1993; 16: 299-321
15. Jaber M, Robinson SW, Missale C, et al. Dopamine receptors and brain function. Neuropharmacology 1996; 35: 1503-19
16. 3H]-spiperone labels dopamine receptors in pituitary and brain. Eur J Pharmacol 1977; 46: 377-81
17. Demchyshyn LL, Sugamori KS, Lee FJS, et al. The dopamine D1D receptor: cloning and characterization of three pharmacologically distinct D1-like receptors from Gallus domesticus. J Biol Chem 1995; 270: 72-6
18. 123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology 2002; 162: 42-9
19. Hersch SM, Ciliax BJ, Gutekunst CA, et al. Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationship with motor corticostriatal afferents. J Neurosci 1995; 15: 5222-37
20. Nyberg S, Nakashima Y, Nordstrom AL, et al. Positron emission tomography of in vivo binding characteristic of atypical antipsychotic drugs: review of D2 and 5-HT2 receptor occupancy studies and clinical response. Br J Psychiatry 1996; 168: 40-4
21. Farde L, Halldin C. D2 dopamine receptors in schizophrenia. In: Fog R, Garlach J, Hemmingsen R, editors. Alfred Benzon symposium 38: Schizophrenia, an integrated view. Copenhagen: Munksgaard, 1995: 190-9
22. Diaz J, Levesque D, Griffon N, et al. Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience 1995; 65: 731-45
23. Bristow LJ, Kramer MS, Kulagowski J, et al. Schizophrenia and L-745870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci 1997; 18: 186-8
24. Deberdt R. Pipamperone in the treatment of behavior disorders: a large scale multicentre evaluation. Acta Psyciatr Belg 1976; 76: 157-66
25. Ansoms C, De Backer-Dierick G, Vereecken JLTM. Sleep disorders in patients with severe mental depression: double-blind placebo-controlled evaluation of the value of pipamperone. Acta Psychiatr Scand 1977; 55: 116-22
26. Leysen JE, Gommeren W, Van Gompel P. Receptor binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 1985; 27: 600-11
27. Bersani G, Grispini A, Marini S, et al. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990; 13: 500-6
28. Leysen JE, Janssen PM, Gommeren W, et al. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotic risperidone and ocaperidone. Mol Pharmacol 1992; 41: 494-508
29. Megens AA, Awouters FH, Schotte A, et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology 1994; 114: 9-23
30. Janssen PA, Niemegeers CJ, Awouters F, et al. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 1998; 244: 685-93
31. Davis JM, Janicak PG. Risperidone: a new, novel (and better?) antipsychotic? Psychiatr Ann 1996; 26: 9-23
32. Gallhofer B, Bayer U, Lis S, et al. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 1996; 6: S13-20
33. Katz R, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbance associated with dementia: a randomized, double-blind trial. J Clin Psychiatr 1999; 60: 107-15
34. Leysen JE, Janssen PM, Schotte A, et al. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5-HT2 receptors. Psychopharmacology 1993; 112: S40-54
35. Leysen JE, Gommeren W, Mertens J, et al. Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors and for D2 receptors in rat striatal and mesolimbic tissues using [125I ]2′-iodospiperone. Psychopharmacology 1993; 110: 27-36
36. Gellman RL, Aghajanian GK. Serotonin2 receptor-mediated excitation of interneurons in piriform cortex: antagonism by atypical antipsychotic drugs. Neuroscience 1994; 58: 515-25
37. Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 1991; 43: 587-604
38. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46: 157-203
39. Hoyer D, Martin G. R. Classification and nomenclature of 5-HT receptors: a comment on current issues. Behav Brain Res 1996; 73: 263-8
40. To Z. P, Bonhaus DW, Eglen RM, et al. Characterization and distribution of putative 5-HT7 receptors in guinea pig brain. Br J Pharmacol 1995; 115: 107-16
41. Tamminga CA. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 1998; 12: 21-36
42. Lidsky TI, Bannerjce SP. Contribution of glutamatergic dysfunction to schizophrenia. Drug News Perspect 1996; 9: 453-9
43. Kim JS, Kornhuber HH, Schmid-Burgk W, et al. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 1980; 20: 379-82
44. Toru M, Watanabe S, Shibuya H, et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 1988; 78: 121-37
45. Sherman AD, Davidson AT, Baruah S. et al. Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett 1991; 121: 77-80
46. Sherman AD, Hegwood TS, Bamah S, et al. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biol Psychiatry 1991; 30: 1191-8
47. Melby Jr EC, Baker HJ. Phencyclidine for analgesia and anesthesia in simian primates. J Am Vet Med Assoc 1965; 147: 1068-72
48. Anis NA, Berry SC, Burton NR, et al. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 1983; 79: 565-75
49. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-8
50. Allen RM, Young SJ. Phencyclidine-induced psychosis. Am J Psychiatry 1978; 135: 1081-4
51. Simpson MD, Slater P, Royston MC, et al. Alterations in phencyclidine and sigma binding sites in schizophrenic brains: effects of disease process and neuroleptic medication. Scizophr Res 1991; 6: 41-8
52. Snyder SH. Phencyclidine. Nature 1980; 285: 355-6
53. Luisada PV. The phencyclidine psychosis: phenomenology and treatment. NIDA Res. Monogr 1978; 21: 241-53
54. Petersen R. C, Stillman R. C. Phencyclidine: an overview. NIDA Res Monogr 1978; 21: 1-17
55. Nishikawa T, Takashima M, Toru M. Increased [3H] kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 1983; 40: 245-50
56. Healy DJ, Haroutonian V, Powchik P, et al. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology 1998; 19: 278-86
57. Rogers GA, Thorell JO, Johnstrom P, et al. Ampakines: labelling with 11C for PET distribution studies. J Labelled Comp Radiopharm 1997; 40: 645-7
58. Araj A, Kessler M, Rogers G, et al. Effects of a memory-enhancing drug on DL-[Unsupported Character]-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus [abstract]. J Pharmacol Exp Ther 1996; 278: 627-38
59. Staubli U, Perez Y, Xu FB, et al. Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo [abstract]. Proc Natl Acad Sci U S A 1994; 91: 11158-62
60. Staubli U, Rogers G, Lynch G. Facilitation of glutamate receptors enhances memory [abstract]. Proc Natl Acad Sci U S A 1994; 91: 777-81
61. Ingvar M, Ambros-Ingerson J, Davis M, et al. Enhancement by an ampakine of memory encoding in humans. Exp Neurol 1997; 146: 553-9
62. Larson J, Quach CN, LeDuc BQ, et al. Effects of an AMPA receptor modulator on metamphetamine-induced hyperactivity in rats. Brain Res 1996; 738: 353-6
63. Goff DC, Leahy L, Berman I, et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 2001; 21: 484-7
64. 3H]-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 1989; 77: 231-6
65. Toru M, Kurumaji A, Ishimaru M. Excitatory amino acids: implications for psychiatric disorders research. Life Sci 1994; 55: 1683-99
66. Ishimaru M, Kurumaji A, Toru M. NMDA-associated glycine binding site increases in schizophrenic brains. Biol Psychiatry 1992; 32: 379-81
67. 3H]-glutamic acid release by dopaminergic drugs. Life Sci 1980; 26: 2073-81
68. Maura G, Carbone R, Raiteri M. Aspartate-releasing nerve terminals in rat striatum possess D2 dopamine receptors mediating inhibition of release. J Pharmacol Exp Ther 1989; 251: 1142-6
69. Yamamoto BK, Davy S. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J Neurochem 1992; 58: 1736-42
70. Chesselet MF. Presynaptic regulation of neurotransmitter release in the brain: facts and hypothesis. Neuroscience 1984; 12: 347-75
71. Giorguieff MF, Le Floc'h ML, Glowinski J, et al. Involvement of cholinergic presynaptic receptors of nicotinic and muscarinic types in the control of the spontaneous release of dopamine from striatal dopaminergic terminals in the rat. J Pharmacol Exp Ther 1977; 200: 535-44
72. 3H]-dopamine release from rat striatum: an in vitro model for glutamate actions. J Neurochem 1979; 32: 1539-45
73. Cheramy A, Romo R, Godeheu G, et al. In vitro presynaptic control of dopamine release in the cat caudate nucleus: II. facilitatory or inhibitory influence of L-glutamate. Neuroscience 1986; 19: 1081-90
74. Deutsch SI, Mastropaolo J, Schwartz BL, et al. A "glutamatergic hypothesis" of schizophrenia: rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989; 12: 1-13
75. Deutsch DG, Koul O, Kersten RS. Phencyclidine and analogues: effects on brain protein synthesis. J Neurochem 1984; 42: 407-11
76. Csernansky JG, Kaplan J, Hollister LE. Problems in classification of schizophrenics as neuroleptic responders and non-responders. J Nerv Ment Dis 1985; 173: 325-31
77. Andreasen NC, Olsen S. Negative vs positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982; 39: 789-94
78. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996; 3: 241-53
79. Davis JM, Andriukaitis S. The natural course of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacol 1986; 6: 2S-10S
80. Bazire S. Psychotropic drug directory 2001/2002. Snow Hill, Dinton, UK: Mark Allen Publishing Ltd, 2001
81. Sanders-Bush E, Sulser F. Drugs used for the treatment of affective disorders. In: Munson PL, editor. Principles of pharmacology, basic concepts & clinical application. New York: Chapman & Hall, 1995: 309-24
82. Martin P, Gozlan H, Puech A. J 5-HT3 receptor antagonists reverse helpless behaviour in rats. Eur J Pharmacol 1992; 212: 73-8
83. Amery W, Marder SR. Safety and switching issues of novel antipsychotics. Int J Psychiatry Clin Pract 1998; 2: S43-9
84. Janssen PA, Awouters F. Antipsychotic drugs. In: Munson PL, editor. Principles of pharmacology, basic concepts & clinical application. New York: Chapman & Hall, 1995: 289-308
85. Gareri P, Falconi U, De Fazio P, et al. Conventional and new antidepressant drugs in the elderly. Prog Neurobiol 2000; 61: 353-96
86. Galeotta G, Paoletti V, Mammarella A, et al. La terapia farmacologica nel paziente anziano. Clin Ter 1990; 135: 181-92
87. Voltz HP, Moeller HJ Antidepressant drug therapy in the elderly: a critical review of the controlled clinical trials conducted since 1980. Pharmacopsychiatry 1994; 27: 93-100
88. Baumann P. Care of depression in the elderly: comparative pharmacokinetics of SSRIs. Int Clin Psychopharmacol 1998; 13: 35-43
89. Greenblatt DJ, Sellers EM, Shader RI. Drug disposition in old age. N Engl J Med 1982; 306: 1081-8
90. Safar M. Ageing and its effects on the cardiovascular system. Drugs 1990; 39: 1-8
91. Bruinink A, Lichtensteiger W. Effects of pH and ascorbic acid on 3H-spiperone and 3H-dihydroalprenolol binding in rat forebrain homogenates. J Recept Res 1984; 4: 127-39
92. Furlanut M, Benetello P, The pharmacokinetics of tricyclic antidepressant drugs in the elderly. Pharmacol Res 1990; 22: 15-25
93. Gareri P, Stilo G, Bevacqua I. et al. Antidepressant drugs in the elderly. Gen Pharmacol 1998; 30: 465-75
94. Montamat SC, Cusack BJ, Yestal RE. Management of drug therapy in the elderly. N Engl J Med 1989; 321: 303-9
95. Mannens G, Meuldermans W, Snoeck E, et al. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology (Berl) 1994; 114: 566-72
96. Rubin EH. Terapia con farmaci psicotropi: precauzioni particolari nell'anziano. Minuti 1987; 5: 11-21
97. Verbeeck RK, Cardinal JA, Wallace SM. Effect of age and sex on the plasma binding of acidic and basic drugs. Eur J Clin Pharmacol 1984; 27: 91-7
98. Alexanderson B, Price Evans DA, Sjoqvist F, Steady state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. BMJ 1969; 2: 764-8
99. Clark DWJ. Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs 1985; 29: 342-75
100. Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2D19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173-92
101. Bertilsson L, Dahl ML, Sjoqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine [letter]. Lancet 1993; 341: 63
102. DeVane CL. Pharmacogenetics and metabolism of newer antidepressant agents. J Clin Psychiatry 1994; 55 (12 Suppl.): 38-45
103. Gonzalez FJ, Skoda RC, Kinenza S. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988; 331: 442-6
104. Gonzalez FJ, Korzekwa KR. Cytochromes P450 expression sites. Ann Rev Pharmacol Toxicol 1995; 35: 369-90
105. Baumann P. Pharmacokinetic pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31: 444-69
106. Brosen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996; 18: 393-6
107. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin reuptake inhibitors on cytochrome P450 2D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262-5
108. Ereshefsky L. Drug-drag interactions involving antidepressants: focus on venlafaxine. J Clin Psychopharmacol 1996; 16: 37S-50S
109. Brunello N. Interazioni farmacocinetiche degli antidepressivi. In: Vella G, Siracusano A, editors. La depressione nell'anziano, Il Pensiero Scientifico editore. NOOS, Rome 1998; 4: 16-28
110. Lamy PP. Geriatric drug therapy. Am Fam Phys 1986; 34: 118-24
111. Beers MH, Ouslander JG. Risk factors in geriatric drug prescribing. Drugs 1989; 37: 105-12
112. Friedman JR, Norman DC, Yoshikawa TT. Correlation of estimated renal function parameters versus 24-hour creatinine clearance in ambulatory elderly. JAGS 1989; 37: 145-9
113. Swift M. The family history in clinical psychiatric practice. Am J Psychiatry 1987; 144: 628-9
114. Micromedex® Healthcare Series. Englewood (CO): MICROMEDEX Inc: 2001
115. Gilman JT, Tuchman RF, Autism and associated behavioral disorders: pharmacotherapeutic intervention. Ann Pharmacother 1995; 29: 47-56
116. Seneff MG, Mathews RA. Use of haloperidol infusions to control delirium in critically ill adults. Ann Pharmacother 1995; 29: 690-3
117. Tisdale JE, Rasty S, Padhi ID, et al. The effect of intravenous haloperidol on QTc interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of torsades de pointes. J Clin Pharmacol 2001; 41: 1310-8
118. Frenchman IB, Prince T. Clinical experience with risperidone, haloperidol and thioridazine for dementia-associated behavioral disturbances. Int Psychogeriatr 1997; 9: 431-5
119. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomised trial of risperidone, placebo and haloperidol for behavioural symptoms of dementia. Neurology 1999; 53: 946-55
120. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000; 17: 363-84
121. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59: 441-8
122. Tesar GE, Stern TA. Rapid tranquilization of the agitated intensive care unit patient. J Intensive Care Med 1988; 3: 195-201
123. Torta R. Prontuario dei farmaci per il Sistema Nervoso Centrale. Turin: Solvay Pharma SPA, 2000
124. Cohen BM, Sommer BR. Metabolism of thioridazine in the elderly. J Clin Psychopharmacol 1988; 8: 336-9
125. Gareri P, Curcio M, Cotroneo A, et al. Efficacy of risperidone vs. promazine in the treatment of behavioral disorders in elderly demented patients [abstract]. International Conference "The role of geriatric departments in general hospitals"; 2002 Apr 17-20; Rome. Geriatria XIV (Suppl) 1: 191
126. McLaren S, Cookson JC, Silverstone T. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of dromperidol and fluphenazine decanoates. Int Clin Psychopharmacol 1992; 7: 67-72
127. Miller RS, Peterson GM, McLean S, et al. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenaziae decanoate. J Clin Pharm Ther 1995; 20: 55-62
128. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine and placebo for the acute treatment of psychosis and behavioural disturbances in hospitalised, demented patients. Am J Psychiatr 2002; 159: 460-5
129. Claveria LE, Teychenne PF, Calne DB, et al. Tardive dyskinesia treated with pimozide. J Neurol Sci 1975; 24: 393-401
130. Wetzel H, Wiesner J, Hiemke C, et al. Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers. J Psychiatr Res 1994; 28: 461-73
131. Pelissolo A, Krebs MO, Olie JP. Traitement des symptomes deficitaires de la schizophrenie par l'amisulpride: revue de la literature. L'Encephale 1996; 22: 215-9
132. Product Information: Solian®, amisulpride tablets. Maidenhead (UK): Lorex Synthelabo, 1999
133. Xiberas X, Martinot JL, Mallet L, et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 2001; 21: 207-14
134. Seminara G, Trassari V, Prestifilippo N, et al. Atypical tricyclic neuroleptics for treatment of schizophrenia: clothiapine and clozapine. Minerva Psichiatr 1993; 34: 95-9
135. Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997; 171: 109-12
136. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics: Part I. pharmacology, pharmacokinetics and efficacy. Ann Pharmacother 1999; 33: 73-85
137. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs 2001; 15: 469-94
138. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998; 44: 778-83
139. Bonanno DG, Davydov L, Botts SR. Olanzapine-induced diabetes mellitus. Ann Pharmacother 2001; 35: 563-5
140. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001; 16: 63-74
141. Gaulin BD, Markowitz JS, Caley CF, et al. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156: 1270-2
142. Ghaeli P, Dufresen RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996; 53: 2079-81
143. Wirshing WC. The new antipsychotic compounds: is a clinical choice algorithm possible? West J Med 1998; 169: 43-4
144. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 68-73
145. Smith H, Kenney-Herbert J, Knowles L. Clozapine-induced diabetic ketoacidosis. Aust N Z J Psychiatry 1999; 33: 120-1
146. Wolters EC, Berendse HW. Management of psychosis in Parkinson's disease. Curr Opin Neurol 2001; 14: 499-504
147. Jeste D. V, Eastham J H, Lohr J B, et al. Treatment of behavioral disorders and psychosis. In: Salzman C, editor. Clinical geriatric psychopharmacology. Baltimore (MD): Williams & Wilkins, 1998; 6: 106-49
148. He H, Richardson JS. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol 1995; 10: 19-30
149. Byerly MJ, De Vane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996; 16: 177-87
150. Wrighton SA, Brian WR, Sari MA, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990; 38: 207-13
151. Pollock BG, Laghrissi-Thode F, Wagner WR, et al. Increased PF4 and β-TG in depressed patients with ischemic heart disease [abstract]. Scientific abstract of the 34th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico; ACNP, Nashville, TN, USA 1995, 101
152. Barak Y, Shamir E, Weizman R. Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients?: a naturalistic, long-term, retrospective, comparative study. J Clin Psychopharmacol 2002; 22: 115-20
153. Gareri P, Cotroneo A, Marchisio U, et al. Risperidone in the treatment of behavioral disorders in elderly patients with dementia. Arch Gerontol Geriatr 2001; 33: 173-82
154. Herrmann N, Rivard MF, Flynn M, et al. Risperidone for the treatment of behavioral disturbances in dementia: a case series. J Neuropsychiatry Clin Neurosci 1998; 10: 220-3
155. Irizarry MC, Ghaemi SN, Lee-Cherry ER, et al. Risperidone treatment of behavioural disturbances in outpatients with dementia. J Neuropsychiatry Clin Neurosci 1999; 11: 336-42
156. Lavretsky H, Sultzer D. A structured trial of risperidone for the treatment of agitation in dementia. Am J Geriatr Psychiatry 1998; 6: 127-35
157. Robertsson B, Karlsson I, Eriksson L, et al. An atypical neuroleptic drug in the treatment of behavioural disturbances and psychotic symptoms in elderly people. Dementia 1996; 7: 142-6
158. Lane HY, Chang YC, Su MH, et al. Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors and mood effects. J Clin Psychopharmacol 2002; 22: 4-10
159. Madhusoodanan S, Brecher M, Brenner R, et al. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Psychiatry 1999; 7: 132-8
160. Davidson M, Harvey PD, Vervarcke J. et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry 2000; 15: 506-14
161. Borison RL, Diamond B, Pathitaja A, et al. Pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacol Bull 1994; 30: 193-7
162. Jeste DV, Eastham JH, Lacro JP, et al. Management of late-life psychosis. J Clin Psychiatry 1996; 57: 39-45
163. Yerrabolu M, Prabhudesai S, Tawam M, et al. Effect of risperidone on QT interval and QT dispersion in the elderly. Heart Dis 2000; 2: 10-2
164. Wirshing DA, Pierre JM, Eyeler J. Risperidone-associated new-onset diabetes. Biol Psychiatry 2001; 15: 278-82
165. Meehan KM, Wang H, David SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam and placebo: a double blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26: 494-504
166. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001; 11: 25-32
167. Kennedy JS, Bymaster FP, Schuh L, et al. A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. Int J Geriatr Psychiatry 2001; 16: S33-61
168. Kennedy JS, Zagar A, Bymaster FP, et al. The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16: S24-32
169. Madhusoodanan S, Sinha S, Brenner R, et al. Use of olanzapine for elderly patients with psychotic disorders: a review. Ann Clin Psychiatry 2001; 13: 201-13
170. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47: 27-38
171. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2000; 57: 968-76
172. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999; 21: 106S-15S
173. Narendran R, Young CM, Valenti AM, et al. Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study. J Clin Psychiatry 2001; 62: 509-16
174. Madhusoodanan S, Brenner R, Suresh P, et al. Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann Clin Psychiatry 2000; 12: 11-8
175. Solomos K, Geiger O. Olanzapine use in the elderly: a retrospective analysis. Can J Psychiatry 2000; 45: 151-5
176. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 2001; 57: 968-76
177. Wolters EC, Jansen EN, Tuynman-Qua HG, et al. Olanzapine in treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47: 1085-7
178. Aarsland D, Larsen JP, Lim NG, et al. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J Neuropsychiatry Clin Neurosci 1999; 11: 392-4
179. Pollak PT, Zbuk K. Quetiapine fumarate overdose: clinical and pharmacokinetic lessons from extreme conditions. Clin Pharmacol Ther 2000; 68: 92-7
180. McConville BJ, Arvanitis LA, Thyrum PT, et al. Pharmacokinetics, tolerability and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. J Clin Psychiatry 2000; 61: 252-60
181. Brecher M, Rak IW, Melvin K, et al. The long-term effect of quetiapine (Seroquel™) monotherapy on weight in patients with schizophrenia. Int J Psych Clin Pract 2000; 4: 287-91
182. Madhusoodanan S, Brenner R, Alcantra A. Clinical experience with quetiapine in elderly patients with psychotic disorders. J Getiatr Psychiatry Neurol 2000; 13: 28-32
183. McManus DQ, Arvanitis LA, Kowalcyk BB. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 study Group. J Clin Psychiatry 1999; 60: 292-8
184. Tariot PN, Salzman C, Yeung PP, et al. Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Ther 2000; 22: 1068-84
185. Green B. Focus on quetiapine. Curr Med Res Opin 1999; 15: 145-51
186. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular halopetidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. J Clin Psychiatry 2000; 61: 933-41
187. Wilner KD, Tensfeldt TG, Baris B, et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 2000; 49, Suppl. 1: 15S-20S
188. Aweeka F, Jayesekara D, Horton M, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 2000; 49 Suppl. 1: 27S-33S
189. Everson G, Lasseter KC, Anderson KE, et al. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function. Br J Clin Pharmacol 2000; 49: 21S-6S
190. Byerly MJ, Weber MT, Brooks DL, et al. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging 2001; 18: 45-61
191. Keck Jr PE, McElroy SL, Arnold LM. Ziprasidone: a new atypical antipsychotic. Exert Opin Pharmacother 2001; 2: 1033 -42
192. Goodnick PJ, Kato MM. Antipsychotic medication: effects on regulation of glucose and lipids. Expert Opin Pharmacother 2001; 2: 1571-82
193. Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther 2002; 24: 21-37
194. Wilner KD, Tensfeldt TG, Baris B, et al. Single- and multiple-dose phannacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 2000; 49: 15S-20S
195. von Bahr C, Movin G, Yisak WA, et al. Clinical pharmacokinetics of remoxipride. Acta Psychiatr Scand Suppl 1990; 358: 41-4
196. Movin-Osswald G, Boelaert J. Hammarlund-Udenaes M, et al. The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function. Br J Clin Pharmacol 1993; 35: 615-22
197. Swift CG, Lee DR, Maskrey VL, et al. Single dose pharmacodynamics of thioridazine and remoxipride in healthy younger and older volunteers. J Psychopharmacol 1999; 13: 159-65
198. Hori M, Suzuki T, Sasaki M, et al. Convulsive seizures in schizophrenic patients induced by zotepine administration. Jpn J Psychiatry Neurol 1992; 46: 161-7
199. Pantel J, Schroder J, Eysenbach K, et al. Two cases of deep vein thrombosis associated with a combined paroxetine and zotepine therapy. Pharmacopsychiatry 1997; 30: 109-11
200. Cooper SJ, Butler A, Tweed J, et al. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia. Psychopharmacol 2000; 150: 237-43
201. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother 2002; 3: 479-98
202. Wong SL, Cao G, Mack RJ, et al. Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Clin Pharmacol Ther 1997; 62: 157-64
203. Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2000
204. Wilton LV, Heeley EL, Pickering RM, et al. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001; 15: 120-6
205. Inoue A, Nakata Y. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy. Jpn. J Pharmacol 2001; 86: 376-80
206. Zanetti O, Binetti G. La terapia farmacologica. In: Trabucchi M, editor. Le demenze. 3rd ed. UTET, Arese (Mi) 2002: 517-38